NCDC directs hospitals to strengthen infection prevention, control practices

Following the rapid spread of Human Metapneumovirus (HMPV) in China, the Nigeria Centre for Disease Control and Prevention (NCDC) has directed hospitals across the country to strengthen Infection Prevention and Control (IPC) practices.

NCDC directed the hospitals to set aside an appropriate isolation room where cases can be quickly isolated while receiving care.

Recent reports indicate a significant rise in Human Metapneumovirus (HMPV) cases in China and increased respiratory infections linked to HMPV in countries such as the United Kingdom (UK), France, and Germany, particularly during the winter season.

The UK Health Security Agency (UKHSA) has highlighted a notable rise in hospital admissions due to HMPV-related complications, especially among children under five and older adults in care homes.

NCDC Director General, Dr. Jide Idris, said that the rise in the HMPV cases indicates the need for heightened preparedness and vigilance.

He observed that in response to the increased HMPV activity in China and other affected regions, as well as growing public interest in the matter, the NCDC in collaboration with the Federal Ministry of Health and Social Welfare is closely monitoring global developments and has implemented some actions to ensure public health safety.

Idris noted that the NCDC in collaboration with the Federal Ministry of Health, the World Health Organization (WHO), the U.S. Centers for Disease Control and Prevention (USCDC), and the UK Health Security Agency (UKHSA) have conducted a dynamic risk assessment of the HMPV and the assessment classified the risk as moderate for Nigeria.

He observed that this evaluation will inform and guide preparedness efforts, decision-making, and response strategies to mitigate potential impacts.

The Director General explained that HMPV is a respiratory virus that can cause illnesses ranging from mild cold-like symptoms to severe respiratory infections, particularly in young children, older adults, and individuals with weakened immune systems adding that there is no specific antiviral treatment or vaccine for HMPV

He noted that the symptoms include cough, fever, nasal congestion, shortness of breath and wheezing

Idris noted that the centre in collaboration with Port Health Authorities is taking proactive steps to ensure robust preparedness at all international points of entry (PoEs) in response to the dynamic risk assessment of the HMPV adding that these measures are designed to mitigate the potential risk of HMPV transmission through international travel.

According to him, key actions include conducting a comprehensive situation analysis at all international PoEs to assess current readiness levels.

Idris observed that an Entry Implementation Protocol on HMPV, approved by the Coordinator Minister of Health and Social Welfare, is being developed and will be distributed to all points of entry to guide response activities while quarantine facilities are being identified and prepared to manage any suspected or confirmed cases if required.